- GlobeNewswire•6 days agoPortola Pharmaceuticals Announces AndexXa™ (andexanet alfa), Betrixaban and Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., Nov. 28, 2016-- Portola Pharmaceuticals today announced that clinical and preclinical results from studies of all three of its investigational drugs-- AndexXa™, betrixaban ...
- GlobeNewswire•19 days agoPortola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Ill Patients with Extended-Duration Betrixaban
NEW ORLEANS and SOUTH SAN FRANCISCO, Calif., Nov. 14, 2016-- Portola Pharmaceuticals, Inc. ® today announced results from three substudies of the pivotal Phase 3 APEX Study of betrixaban, an oral, once-daily ...
PTLA : Summary for Portola Pharmaceuticals, Inc. - Yahoo Finance
Portola Pharmaceuticals, Inc. (PTLA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||10.50 x 100|
|Ask||18.80 x 500|
|Day's Range||17.15 - 18.14|
|52 Week Range||15.68 - 52.89|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.55|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|